SEC 13F Intelligence

Managers / Q4 2019 · view latest →

Boxer Capital, LLC

CIK 0001465837 · 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130 · (858) 400-3112

Reported Value
$1.8B
Q4 2019
Positions
51
Filings on Record
27
2019–present window
Filed
Feb 14, 2020
original filing

Summary

Boxer Capital, LLC reported $1.8B in U.S.-listed holdings across 51 positions for Q4 2019.

Its largest position, MRTXEUR, represents 12.5% of the portfolio.

Compared with Q3 2019, the fund opened 13 new positions and exited 11.

Portfolio Metrics

Turnover
+24.1%
vs prior filed quarter
Top-10 Concentration
+60.6%
share of reported value
Largest Position
+12.5%
Mirati Therapeutics
New / Exited
13 / 11
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $809MQ4 ’18Q1 ’19: $865MQ2 ’19: $1.2BQ3 ’19: $1.4BQ3 ’19Q4 ’19: $1.8BQ1 ’20: $1.5BQ2 ’20: $2.3BQ2 ’20Q3 ’20: $2.9BQ4 ’20: $3.1BQ1 ’21: $2.9BQ1 ’21Q2 ’21: $2.8BQ3 ’21: $2.9BQ4 ’21: $2.6BQ4 ’21Q1 ’22: $1.9BQ2 ’22: $1.6BQ3 ’22: $1.8BQ3 ’22Q4 ’22: $1.9BQ2 ’23: $2MQ4 ’23: $2.0BQ4 ’23Q1 ’24: $2.0BQ2 ’24: $1.9BQ3 ’24: $2.0BQ3 ’24Q4 ’24: $0filingsflow.com

Portfolio Composition

By security type
Common Stock: 70.8%Other: 16.7%ADR: 10.5%ETP: 2.0%
  • Common Stock · 70.8% · $1.3B
  • Other · 16.7% · $296M
  • ADR · 10.5% · $185M
  • ETP · 2.0% · $36M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
SGENUSDSEATTLE GENETICS INCNEW+500.0K500.0K+$57M$57M
DIREXION SHS ETF TRNEW+2.88M2.88M+$36M$36M
SG7SAGE THERAPEUTICS INCNEW+350.0K350.0K+$25M$25M
CABACABALETTA BIO INCNEW+1.57M1.57M+$22M$22M
ANABANAPTYSBIO INCNEW+1.30M1.30M+$21M$21M
BARCLAYS BK PLCNEW+1.00M1.00M+$15M$15M
ARVNARVINAS INCNEW+366.0K366.0K+$15M$15M
NEOLEUKIN THERAPEUTICS INCNEW+1.01M1.01M+$12M$12M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2019

49 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1MRTXEURMIRATI THERAPEUTICS INChistory →COM12.50%$221M1.72M
2IMMUIMMUNOMEDICS INChistory →COM10.11%$179M8.45M
3ONCBEIGENE LTDhistory →SPONSORED ADR8.67%$153M925.0K
4ODONATE THERAPEUTICS INCCOM6.17%$109M3.36M
5MDCOUSDMEDICINES COhistory →COM4.65%$82M967.0K
6SWTXUSDSPRINGWORKS THERAPEUTICS INChistory →COM4.52%$80M2.08M
7DBV TECHNOLOGIES S ASPONSORED ADR3.86%$68M6.38M
8ALLKGUSDALLAKOS INChistory →COM3.64%$64M675.0K
9ESPRESPERION THERAPEUTICS INC NEhistory →COM3.29%$58M975.0K
10SGENUSDSEATTLE GENETICS INChistory →COM3.23%$57M500.0K
11UNIQURE NVSHS3.10%$55M765.4K
12DIREXION SHS ETF TRDAILY S&P BIOTEC2.02%$36M2.88M
13GOSSGOSSAMER BIO INChistory →COM1.93%$34M2.19M
14RCKTROCKET PHARMACEUTICALS INChistory →COM1.89%$33M1.47M
15ARGXARGENX SEhistory →SPONSORED ADR1.82%$32M200.0K
16SRPTSAREPTA THERAPEUTICS INChistory →COM1.64%$29M225.0K
17KDMNKADMON HLDGS INChistory →COM1.59%$28M6.21M
18ATRECA INCCL A COM1.52%$27M1.73M
19SG7SAGE THERAPEUTICS INChistory →COM1.43%$25M350.0K
20APLSUSDAPELLIS PHARMACEUTICALS INChistory →COM1.39%$24M800.0K
21MTNBEURMATINAS BIOPHARMA HLDGS INChistory →COM1.31%$23M10.19M
22AM6AMICUS THERAPEUTICS INChistory →COM1.28%$23M2.33M
23CABACABALETTA BIO INChistory →COM1.24%$22M1.57M
24BMRNBIOMARIN PHARMACEUTICAL INChistory →COM1.20%$21M250.0K
25ANABANAPTYSBIO INChistory →COM1.19%$21M1.30M
26GBTUSDGLOBAL BLOOD THERAPEUTICS INhistory →COM1.12%$20M250.0K
27ACHNEURACHILLION PHARMACEUTICALS INhistory →COM1.03%$18M3.00M
28PREVAIL THERAPEUTICS INCCOM1.01%$18M1.12M
29MISTMILESTONE PHARMACEUTICALS INhistory →COM1.00%$18M1.10M
30RCUSARCUS BIOSCIENCES INChistory →COM0.96%$17M1.67M
31BARCLAYS BK PLCIPATH B SHRT TRM0.86%$15M1.00M
32ARVNARVINAS INChistory →COM0.85%$15M366.0K
33BLUBELLUS HEALTH INC NEWhistory →COM NEW0.76%$13M1.77M
34NEOLEUKIN THERAPEUTICS INCCOM0.70%$12M1.01M
35RLMDRELMADA THERAPEUTICS INChistory →COM0.66%$12M300.0K
36KURAKURA ONCOLOGY INChistory →COM0.66%$12M844.8K
37LXRXLEXICON PHARMACEUTICALS INChistory →COM NEW0.65%$12M2.77M
38AKROAKERO THERAPEUTICS INChistory →COM0.61%$11M482.5K
39MRNSUSDMARINUS PHARMACEUTICALS INChistory →COM0.59%$10M4.80M
40SELECTA BIOSCIENCES INCCOM0.44%$8M3.28M
41MIRMMIRUM PHARMACEUTICALS INCCOM0.44%$8M317.0K
42MEI PHARMA INCCOM NEW0.41%$7M2.91M
43IDYAIDEAYA BIOSCIENCES INCCOM0.32%$6M764.3K
44SOLID BIOSCIENCES INCCOM0.26%$5M1.03M
45CYMABAY THERAPEUTICS INCCOM0.22%$4M2.00M
464XC1KALVISTA PHARMACEUTICALS INCCOM0.20%$4M200.0K
47KINIKSA PHARMACEUTICALS LTDCOM CL A0.18%$3M290.6K
48LJPCLA JOLLA PHARMACEUTICAL COCOM PAR $.0001 20.17%$3M775.0K
49SNDXSYNDAX PHARMACEUTICALS INCCOM0.12%$2M250.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q4 2024$01Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$2.0B68Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$1.9B61Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$2.0B59May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$2.0B52Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023Under review73Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$2M79Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023Under review75May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$1.9B71Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$1.8B73Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1.6B76Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$1.9B74May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$2.6B71Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$2.9B88Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$2.8B95Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$2.9B85May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$3.1B78Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$2.9B75Nov 17, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$2.3B65Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.5B62May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.8B51Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.4B49Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019REVEALED$1.2B37Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$865M23May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$809M24Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.